Your first month cost one price. Then the dose went up and so did the bill, so why does the dose keep climbing? Nobody ever explained that the two were connected by a business model rather than by your physiology. Dose escalation is how the compounded GLP-1 market makes its margin. Those products are priced by the unit of active ingredient, so every step up in strength is a step up in revenue for the seller. Your dose is the revenue line.
At GoodLife Health the fee is flat and the incentive points the other way. We titrate to the least medicine that gets you the most result, because the $299 monthly fee never changes whether you need the lowest dose or the highest and medication is billed by the pharmacy at pharmacy cost with no markup from anyone in our chain. Here is how the escalation trap works and how to know whether your dose is being set by a clinician or by a spreadsheet.
- Compounded GLP-1 products are priced per unit of active ingredient, so every dose increase raises the seller's revenue.
- Clinical titration aims for the lowest effective dose, not the highest tolerable one.
- The flat $299 fee never changes with dose, which removes any financial incentive to escalate.
- A dose that climbs without a clinical reason is a business decision and you are allowed to ask whose.
The approved titration schedule exists for a reason
Branded GLP-1s carry a label-defined titration schedule, written to manage side effects as the body adapts, not to chase results. Wegovy steps up through five dose levels to a maximum of 2.4 mg weekly. Zepbound steps through its approved strengths toward 15 mg at the ceiling. The schedule is not optional flavor. It exists because jumping to high doses quickly produces nausea, vomiting and other side effects that make people quit and the label is the accumulated evidence of what actually works.
Compounded products, having no label, follow no schedule except the seller's. That is how dose menus advertising 12.5 mg and 15 mg tirzepatide became a marketing feature. Those strengths exceed what any approved product markets as a routine target and a dose menu is a business artifact, not a medical one.
What clinical titration actually looks like
The goal of good prescribing is the lowest effective dose. A clinician titrates upward only when the current dose has stopped producing benefit and side effects are controlled and the decision is anchored to the whole picture: weight trajectory where weight is the goal, biomarkers where they are the goal, side effects always. In our model that picture is the quarterly Biomarker Audit, four panels a year, so the dose conversation happens with fasting insulin, HbA1c and the lipid panel on the table rather than from a scale reading alone.
Two truths follow from that. First, many patients reach their best result at a mid dose and stay there for years. Second, some patients genuinely need the highest approved dose and a flat-fee model never penalizes them for it. The difference between those two patients is clinical and the only way to know which one you are is with a clinician who has no financial stake in your answer.
The three questions that expose a dose-revenue link
Ask any platform three questions and the structure becomes visible. First, does my monthly price change if my dose changes? In a compounded program the answer is usually yes, because the product is billed by the milligram. Second, who decides when my dose goes up? If the answer involves a protocol that moves everyone upward on a clock rather than a clinician reading your response, the escalation is administrative. Third, is the medication brand-name product from a named pharmacy? If it is compounded, the milligram pricing is already in place and the incentive question answers itself.
We will answer the same three questions the other way. Our fee is $299 a month whatever the dose. Dose decisions belong to your clinician, guided by the quarterly audit and the goal is the least medicine that gets the result. And our prescriptions are branded, FDA-approved product only, Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo, never compounded, sent to the pharmacy you choose and billed by that pharmacy at its own price.
One flat fee for the doctor. Zero markup on the medicine. That structure is not a slogan. It is the only arrangement in which nobody in the chain profits when your dose goes up.
The two-month start and what it covers
The membership begins with a single $598 charge covering the first two months together, not $299 plus a separate fee. It includes the first Biomarker Audit, the clinical intake visit, month two of clinical care and the platform costs of running the service. From month three it is $299 a month, month to month and you can cancel anytime. The hold is placed at sign-up and charged only once a clinician accepts you into care. If the clinician cannot accept you, the hold is released and you are never charged. Once accepted, the first two months are charged and non-refundable.
We are direct about this because the honest version of the math is the only kind that belongs in healthcare pricing. Twelve months in the membership is $598 plus ten months at $299, which is $3,588 for a year of clinical care with quarterly labs. There is no year-end surprise, no escalation clause and no dose-based repricing anywhere in it.
The membership is $299 a month with a two-month start: $598 for the first two months, held at sign-up and charged only once a clinician accepts you. The fee never changes with your dose. Medication is billed separately by the pharmacy at pharmacy cost with zero markup, branded and FDA-approved only.
Who this is for and who it is not for
This is for the reader whose dose has climbed alongside their bill, who suspects the two lines are connected and wants the incentive question answered honestly. It suits the person who wants their dose set by a clinician reading their labs, not by a pricing table.
It is not for someone who wants the highest dose available as a goal in itself. Dose is a means, not an achievement and we will not pretend otherwise. And it is not for anyone outside the United States, because our clinicians are licensed in the fifty states.
FAQ
Why does my GLP-1 dose keep climbing?
In compounded programs the dose usually climbs because the product is priced per milligram, so each step up raises the seller's revenue. Clinical titration follows the approved label, moves only when the current dose has stopped working and aims for the lowest effective dose rather than the highest tolerable one.
Is a higher dose always better?
No. Higher doses bring more side effects and many patients reach their best sustainable result at a mid dose. The evidence-based approach titrates to response, read against biomarkers and side effects and stops when the goal is met.
Does my GoodLife Health fee change if my dose goes up?
No. The fee is $299 a month whether you need the lowest dose or the highest approved one, because medication is billed separately by the pharmacy at pharmacy cost and we take nothing from that transaction.
Who decides when my dose increases?
Your clinician does, guided by your response and the quarterly Biomarker Audit. There is no automatic escalation clock and no protocol that moves patients upward on a schedule regardless of response.
Why do some programs advertise 15 mg tirzepatide doses?
Because compounded products have no FDA label limiting them, so sellers can compound and advertise strengths beyond what any approved product markets routinely. Dose menus are a business feature of the compounded market, not a clinical one.
What does the first charge cover?
The $598 first charge covers the first two months together, including the first Biomarker Audit and the clinical intake. It is held at sign-up and charged only once a clinician accepts you into care. From month three the membership is $299 a month and you can cancel anytime.
Is this available outside the United States?
No. Our clinicians are licensed to practice in the fifty states and the membership serves United States residents only.
One last thing
If your dose has gone up twice and your bill has gone up twice, you already understand the model you are in. The question is whether anyone in that chain profits from the next increase. If you want the answer to be no, the eligibility check is free, takes a few minutes and never results in a charge unless a clinician accepts you into care.
Related Guides
- Zepbound vials and the dose-stable fee argument
- How Zepbound dosing escalates week by week
- Is my GLP-1 compounded? How to tell
- Is a GLP-1 worth it at $299 a month